These data also suggest that an early treatment with xanthine oxidase inhibitors might provide therapeutic advantage by delaying or even halting the progression of non-alcoholic fatty liver disease. The gene discussed is XDH; the disease is metabolic dysfunction-associated steatotic liver disease.